The US Department of Justice has reclassified medical marijuana from Schedule I to Schedule III, reducing its regulatory restrictions. This change means FDA-approved and state-licensed medical marijuana is now considered less dangerous, which could open up new business opportunities and investment in the cannabis sector. Tilray's CEO Irwin Simon praised the move, highlighting its positive impact on the industry. This regulatory shift is expected to encourage growth and innovation in medical cannabis markets.
The cannabis industry is expanding rapidly with cannabis now classified as a Class 3 substance, reducing legal barriers for operators. This shift allows for more research, product development, and growth opportunities for both cannabis producers and ...
Tilray Brands, a global leader in cannabis and consumer packaged goods, will announce its financial results for the fourth quarter and full fiscal year ending May 31, 2026, on July 28, 2026, after market close. The company will hold a live conference...
BrewDog Waterloo, England's largest pub owned by Tilray Brands, is set to host a major watch party for the England vs Argentina semifinal. The event promises an electric atmosphere with giant screens and passionate fans. Tilray's £1 million bar tab p...
